Pegpleranib

Drug Profile

Pegpleranib

Alternative Names: E-10030; E01AJ; Fovista; OAP-030; Pegpleranib sodium; X01E

Latest Information Update: 01 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Archemix Corporation
  • Developer National Eye Institute; OphthoTech Corporation
  • Class Eye disorder therapies; Oligonucleotides; Peptide aptamers
  • Mechanism of Action Angiogenesis inhibitors; Platelet-derived growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Wet age-related macular degeneration
  • Phase I/II Von Hippel-Lindau disease
  • Research Retinoblastoma

Most Recent Events

  • 26 Jul 2017 Early research in Retinoblastoma in USA (Intravitreous)
  • 26 Jul 2017 Ophthotech plans preclinical studies for Retinoblastoma in USA
  • 16 May 2017 OphthoTech Corporation completes a phase IIa trial for Wet age-related macular degeneration in France (Treatment-naive, Combination therapy, In the elderly, In adults) (EudraCT2015-000519-42)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top